This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CLN3 | |
|---|---|
| Name | CLN3 |
| Other names | Battenin |
| Location | Human chromosome 16 |
| Clinical association | Juvenile Neuronal Ceroid Lipofuscinosis |
CLN3 CLN3 is a human gene encoding a transmembrane lysosomal protein implicated in juvenile Batten disease. It was identified through linkage studies and positional cloning in families studied by institutions such as University of Cambridge, Harvard University, Massachusetts General Hospital, Mayo Clinic, and Johns Hopkins University Hospital; subsequent research involved collaborations with groups at Max Planck Society, Cold Spring Harbor Laboratory, Scripps Research Institute, and Howard Hughes Medical Institute. The gene has been the subject of studies involving model organisms and consortia including National Institutes of Health, European Molecular Biology Laboratory, Wellcome Trust, European Research Council, and patient advocacy organizations such as Batten Disease Support and Research Association.
CLN3 was first localized in linkage studies relying on pedigree analyses from families in cohorts collected at Addenbrooke's Hospital, Great Ormond Street Hospital, Boston Children's Hospital, and St. Jude Children's Research Hospital. Early descriptions of the clinical syndrome were reported in clinical series at Hopkins Children’s Hospital and historical neuropathological reports from institutions like Mayo Clinic Hospital. Molecular characterization drew on resources from sequencing centers including Wellcome Sanger Institute and Broad Institute. Key collaborative meetings occurred at venues such as Cold Spring Harbor Laboratory meetings and conferences organized by International Society for Neurochemistry.
The CLN3 gene maps to chromosome 16p12.1 and was cloned using approaches pioneered at University of California, San Francisco and University of Oxford laboratories. The canonical CLN3 transcript encodes a membrane protein of approximately 438 amino acids with multiple predicted transmembrane domains; structural predictions have referenced techniques developed at European Bioinformatics Institute and modeling frameworks influenced by research from Stanford University. Mutational spectra include the common 1-kilobase deletion identified in cohorts studied at Aarhus University Hospital, Karolinska Institutet, and University of Toronto. Structural-functional insights have been informed by cryo-EM and computational methods developed by groups at EMBL-EBI, Max Planck Institute for Biophysical Chemistry, and University of California, Berkeley.
CLN3 expression is highest in neural tissues characterized in atlases generated by Allen Institute for Brain Science and comparative expression studies at Cold Spring Harbor Laboratory and National Human Genome Research Institute. Developmental regulation was profiled using datasets from projects including ENCODE and GTEx and validated in model systems maintained at The Salk Institute and University College London. Regulatory elements and transcriptional control have been mapped using chromatin assays from consortia such as Roadmap Epigenomics Consortium; post-transcriptional regulation has been studied in contexts explored by laboratories at Massachusetts Institute of Technology and University of Pennsylvania.
Protein localization studies using methodologies refined at National Institutes of Health and Max Delbrück Center place the CLN3 protein at endolysosomal membranes, synaptic compartments, and Golgi-associated membranes. Functional assays leveraging techniques developed at Dana-Farber Cancer Institute, Scripps Research Institute, and Fred Hutchinson Cancer Center implicate the protein in lysosomal pH maintenance, membrane trafficking, and autophagy pathways. Interactions with SNARE complexes and endosomal sorting machinery were explored in collaborations involving European Molecular Biology Laboratory, University of Cambridge, and Columbia University.
Juvenile NCL associated with CLN3 mutations was characterized clinically and genetically by groups at Johns Hopkins Hospital, Boston Children’s Hospital, and Hospital for Sick Children (Toronto). Pathological hallmarks include neuronal lipofuscin accumulation described in neuropathology studies from Mayo Clinic, Cleveland Clinic, and Mount Sinai Hospital. Natural history studies have been coordinated by multicenter networks including European Reference Network and Batten Disease Registry, with genotype-phenotype correlations reported in consortia publications from NIH Rare Diseases Clinical Research Network.
Patients with CLN3-related disease present with progressive visual failure, seizures, cognitive decline, and motor deterioration—clinical patterns documented in case series from Great Ormond Street Hospital, Boston Medical Center, Sheffield Children’s Hospital, and Royal Children's Hospital (Melbourne). Diagnostic workflows employ neuroimaging protocols standardized at Mayo Clinic, electrophysiology methods from Guy's and St Thomas' NHS Foundation Trust, and genetic testing services at Ambry Genetics, Invitae, and university diagnostic labs such as those at University of Washington. Ophthalmological assessments referenced practices at Wills Eye Hospital and visual rehabilitation centers including Johns Hopkins Wilmer Eye Institute.
Mechanistic studies implicate disrupted lysosomal function, altered autophagy, impaired endocytic trafficking, and synaptic dysfunction; key experimental models include murine lines developed at The Jackson Laboratory, zebrafish models from Karolinska Institutet, and Drosophila models studied at University of Cambridge. Cellular signaling pathways linked to CLN3 pathology have been probed using proteomics platforms at European Proteomics Association centers and metabolomics pipelines at Imperial College London laboratories. Histopathological analyses referenced methods and collections at Royal College of Surgeons and Institut Pasteur.
Therapeutic strategies encompass gene therapy trials coordinated with centers such as University of Pennsylvania, St. Jude Children's Research Hospital, and Baylor College of Medicine; enzyme replacement and small-molecule approaches have involved collaborations with pharmaceutical companies and translational institutes like Genentech, Novartis, Pfizer, AstraZeneca, and GlaxoSmithKline. Patient-centered research networks including Global Genes and European Organisation for Rare Diseases support clinical trial infrastructures modeled after consortia such as Orphanet and International Rare Diseases Research Consortium. Ongoing directions emphasize genome editing approaches inspired by work at Broad Institute and CRISPR Therapeutics, advanced delivery methods investigated at MIT Koch Institute, and biomarker discovery programs at National Cancer Institute.
Category:Human genes Category:Lysosomal storage diseases